UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000019501
Receipt number R000022547
Scientific Title Evaluation of efficacy of dose-adjusted intravenous busulfan in allogeneic hematopoietic stem cell transplantation by analyzing busulfan concentration in dried blood spot method.
Date of disclosure of the study information 2015/11/01
Last modified on 2015/10/26 13:48:09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of efficacy of dose-adjusted intravenous busulfan in allogeneic hematopoietic stem cell transplantation by analyzing busulfan concentration in dried blood spot method.

Acronym

Evaluation of efficacy of dose-adjusted intravenous busulfan by DBS method.

Scientific Title

Evaluation of efficacy of dose-adjusted intravenous busulfan in allogeneic hematopoietic stem cell transplantation by analyzing busulfan concentration in dried blood spot method.

Scientific Title:Acronym

Evaluation of efficacy of dose-adjusted intravenous busulfan by DBS method.

Region

Japan


Condition

Condition

Hematological malignancy

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Evaluation of safety and efficacy of dose-adjusted intravenous busulfan by analyzing busulfan concentration under the conditioning regimen.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The proportion of patients with event-free survival in 100 days after transplantation

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Dose-adjusted intravenous busulfan

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit

70 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Hematological malignancy for AML, MDS, CML, ALL, ML and MM
2. Performance status(PS, ECOG) of 0-2
3. Patients without major organ dysfunction
4. T.Bil less than 2.0 mg/dL
5. AST and ALT less than 3 upper limit of the normal range
6. SCr less than 2.0mg/dl
7. Heart ejection fraction more than 40%
8. SpO2 more than 93%
9. Patients requird to have an appropriate donor identified before enrollment.
(1) HLA-matched related or unrelated donor
(2) 1 HLA-mismatched related or unrelated donor
(3) Cord blood with nucleated cell counts more than 1.5 107/kg and mismatched HLA less than 2
10. Ability to provide informed consent.

Key exclusion criteria

1. positive for anti-HIV antibody
2. positive for Hbs antigen
3. active another malignancy
4. uncontrollable psychological disorders
5. uncontrollable active infection
6. known hypersensitivity to busulfan
7. pregnant women
8. Patients judged as inappropriate for this study by physicians

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yasunori Ueda

Organization

Kurashiki Central Hospital

Division name

Department of Hematology / Oncology

Zip code


Address

1-1-1 Miwa, Kurasiki, Okayama

TEL

086-422-0210

Email

ueda-y@kchnet.or.jp


Public contact

Name of contact person

1st name
Middle name
Last name Aki Sato

Organization

Kurashiki Central Hospital

Division name

Department of Hematology / Oncology

Zip code


Address

1-1-1 Miwa, Kurasiki, Okayama

TEL

086-422-0210

Homepage URL


Email

as14404@kchnet.or.jp


Sponsor or person

Institute

Kurashiki Central Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 11 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2015 Year 03 Month 30 Day

Date of IRB


Anticipated trial start date

2015 Year 11 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 10 Month 26 Day

Last modified on

2015 Year 10 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022547


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name